AU2022381187A1 - Pi3k-alpha inhibitors and methods of making and using the same - Google Patents

Pi3k-alpha inhibitors and methods of making and using the same Download PDF

Info

Publication number
AU2022381187A1
AU2022381187A1 AU2022381187A AU2022381187A AU2022381187A1 AU 2022381187 A1 AU2022381187 A1 AU 2022381187A1 AU 2022381187 A AU2022381187 A AU 2022381187A AU 2022381187 A AU2022381187 A AU 2022381187A AU 2022381187 A1 AU2022381187 A1 AU 2022381187A1
Authority
AU
Australia
Prior art keywords
compound
iii
solid
formula
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022381187A
Other languages
English (en)
Inventor
Alessandro Boezio
Qinglin Che
Jiahui Chen
Xijian GONG
Wei Gu
Hongyan He
Siyi Jiang
André LESCARBEAU
Yuan Lin
Min Lu
Surendra P. Singh
Xiaohong Wang
Changbo YIN
Jiajia Zhou
Qiuxiang ZHOU
Yunfei Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Relay Therapeutics Inc
Original Assignee
Relay Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Relay Therapeutics Inc filed Critical Relay Therapeutics Inc
Publication of AU2022381187A1 publication Critical patent/AU2022381187A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/02—Sulfonic acids having sulfo groups bound to acyclic carbon atoms
    • C07C309/03—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C309/04—Sulfonic acids having sulfo groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton containing only one sulfo group
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/33—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems
    • C07C309/34—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of six-membered aromatic rings being part of condensed ring systems formed by two rings
    • C07C309/35—Naphthalene sulfonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2022381187A 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same Pending AU2022381187A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263474P 2021-11-03 2021-11-03
CNPCT/CN2021/128533 2021-11-03
US63/263,474 2021-11-03
CN2021128533 2021-11-03
PCT/US2022/079221 WO2023081757A1 (en) 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same

Publications (1)

Publication Number Publication Date
AU2022381187A1 true AU2022381187A1 (en) 2024-05-16

Family

ID=86242193

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022381187A Pending AU2022381187A1 (en) 2021-11-03 2022-11-03 Pi3k-alpha inhibitors and methods of making and using the same

Country Status (12)

Country Link
EP (1) EP4426314A4 (https=)
JP (1) JP2024540303A (https=)
KR (1) KR20240112283A (https=)
CN (1) CN118401245A (https=)
AU (1) AU2022381187A1 (https=)
CA (1) CA3236861A1 (https=)
CL (1) CL2024001364A1 (https=)
IL (1) IL312466A (https=)
MX (1) MX2024005429A (https=)
PE (1) PE20250676A1 (https=)
TW (1) TW202334136A (https=)
WO (1) WO2023081757A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4143196A4 (en) 2020-04-29 2024-04-17 Relay Therapeutics, Inc. PI3K-A INHIBITORS AND METHODS OF USE THEREOF
WO2024055992A1 (zh) * 2022-09-14 2024-03-21 南京再明医药有限公司 三环化合物及其应用
TW202541794A (zh) 2022-11-02 2025-11-01 美商佩特拉製藥公司 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點
KR20260005985A (ko) 2023-05-05 2026-01-12 일라이 릴리 앤드 캄파니 Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010007100A1 (en) * 2008-07-15 2010-01-21 Cellzome Ltd 7-substituted amino triazoles as pi3k inhibitors
PE20161323A1 (es) * 2013-09-05 2016-11-25 Hoffmann La Roche Compuestos de triazolopiridina, composiciones y metodos de uso de los mismos
WO2017000277A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2020173935A1 (en) * 2019-02-26 2020-09-03 Boehringer Ingelheim International Gmbh New isoindolinone substituted indoles and derivatives as ras inhibitors
EP4143196A4 (en) * 2020-04-29 2024-04-17 Relay Therapeutics, Inc. PI3K-A INHIBITORS AND METHODS OF USE THEREOF

Also Published As

Publication number Publication date
CA3236861A1 (en) 2023-05-11
JP2024540303A (ja) 2024-10-31
EP4426314A4 (en) 2025-10-01
WO2023081757A1 (en) 2023-05-11
KR20240112283A (ko) 2024-07-18
EP4426314A1 (en) 2024-09-11
CN118401245A (zh) 2024-07-26
PE20250676A1 (es) 2025-03-04
TW202334136A (zh) 2023-09-01
IL312466A (en) 2024-06-01
CL2024001364A1 (es) 2024-10-25
MX2024005429A (es) 2024-05-21

Similar Documents

Publication Publication Date Title
CN114728918B (zh) Rip1抑制性化合物及其制备和使用方法
WO2023060262A1 (en) Pi3k-alpha inhibitors and methods of use thereof
KR102797536B1 (ko) PI3Kα 억제제 및 이의 사용 방법
WO2023081757A1 (en) Pi3k-alpha inhibitors and methods of making and using the same
CA3154862A1 (en) Shp2 phosphatase inhibitors and methods of making and using the same
CA3099037A1 (en) Rip1 inhibitory compounds and methods for making and using the same
TW200806664A (en) Azaindoles useful as inhibitors of janus kinases
JP2021519308A (ja) 転写活性化タンパク質のイミダゾピペラジン阻害剤
CN119486992A (zh) PI3Kα抑制剂及其使用方法
EP4370124A1 (en) PI3Ka INHIBITORS AND METHODS OF USE THEREOF
EP4079748A1 (en) Modulators of sortilin activity
EP4426286A1 (en) Bifunctional pi3k-alpha inhibitors and uses thereof
WO2019189732A1 (ja) 光学活性な架橋型環状２級アミン誘導体
WO2021060453A1 (ja) 架橋型光学活性２級アミン誘導体
CN118201896A (zh) PI3K-α抑制剂和其使用方法
WO2025106788A1 (en) PI3Kα INHIBITORS AND METHODS OF MAKING AND USING THE SAME
WO2024151930A1 (en) Pi3k inhibitors and methods of making and using the same
US20260125374A1 (en) Pi3k-alpha inhibitors and methods of making and using the same
CN118251217A (zh) PI3Kα抑制剂及其使用方法
EA051309B1 (ru) Ингибиторы pi3k-альфа и способы их получения и использования
WO2026044398A1 (en) Salts of 5-chloro-2-fluoro-n-(2-fluoro-4-(3-methyl-4-[(1-methylpiperidin-4-yl)oxy]-1h-pyrazolo[3,4-d]pyrimidin-6-yl)phenyl)benzene sulfonamide and crystalline forms thereof
HK40068242B (en) Rip1 inhibitory compounds and methods for making and using the same
NZ743251A (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide